Atossa Therapeutics Inc (NASDAQ: ATOS) on Monday, soared 11.54% from the previous trading day, before settling in for the closing price of $0.78. Within the past 52 weeks, ATOS’s price has moved between $0.55 and $1.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -21.67%. With a float of $129.12 million, this company’s outstanding shares have now reached $129.17 million.
Let’s determine the extent of company efficiency that accounts for 15 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Atossa Therapeutics Inc (ATOS) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atossa Therapeutics Inc is 0.04%, while institutional ownership is 26.47%. The most recent insider transaction that took place on May 21 ’25, was worth 9,887. In this transaction President & CEO of this company bought 11,239 shares at a rate of $0.88, taking the stock ownership to the 13,898 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 10,000 for $0.70, making the entire transaction worth $7,000. This insider now owns 10,257 shares in total.
Atossa Therapeutics Inc (ATOS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -21.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.52% during the next five years compared to 36.92% growth over the previous five years of trading.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Atossa Therapeutics Inc (ATOS) is currently performing well based on its current performance indicators. A quick ratio of 12.67 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Looking closely at Atossa Therapeutics Inc (NASDAQ: ATOS), its last 5-days average volume was 0.75 million, which is a jump from its year-to-date volume of 0.69 million. As of the previous 9 days, the stock’s Stochastic %D was 24.53%. Additionally, its Average True Range was 0.07.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 60.73%, which indicates a significant increase from 40.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.94% in the past 14 days, which was higher than the 73.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7647, while its 200-day Moving Average is $1.0567. However, in the short run, Atossa Therapeutics Inc’s stock first resistance to watch stands at $0.9179. Second resistance stands at $0.9689. The third major resistance level sits at $1.0379. If the price goes on to break the first support level at $0.7979, it is likely to go to the next support level at $0.7289. Should the price break the second support level, the third support level stands at $0.6779.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
Market capitalization of the company is 111.96 million based on 129,170K outstanding shares. Right now, sales total 0 K and income totals -25,500 K. The company made 0 K in profit during its latest quarter, and -6,720 K in sales during its previous quarter.
